A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma.

Trial Profile

A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 May 2012

At a glance

  • Drugs Carboplatin; Paclitaxel; Sorafenib
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Sep 2009 Celgene Corporation as company and lead trial centre added as reported by ClinicalTrials.gov.
    • 02 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top